Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis

被引:73
作者
Gårdsvoll, H [1 ]
Dano, K [1 ]
Ploug, M [1 ]
机构
[1] Rigshosp, Finsen Lab, DK-2100 Copenhagen O, Denmark
关键词
D O I
10.1074/jbc.274.53.37995
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The urokinase-type plasminogen activator receptor (uPAR) is a glycolipid anchored multidomain member of the Ly-6/uPAR protein domain superfamily. Studies by site-directed photoaffinity labeling, chemical cross-linking, and ligand-induced protection against chemical modification have highlighted the possible involvement of uPAR domain I and particularly loop 3 thereof in ligand binding (Ploug, RI. (1998) Biochemistry 37, 16494-16505). Guided by these results we have now performed an alanine scanning analysis of this region in uPAR by site-directed mutagenesis and subsequently measured the effects thereof on the kinetics of uPA binding in real-time by surface plasmon resonance. Only four positions in loop 3 of uPAR domain I exhibited significant changes in the contribution to the free energy of uPA binding (Delta Delta G greater than or equal to 1.3 kcal mol(-1)) upon single-site substitutions to alanine (i.e. Arg(53), Leu(55), Tyr(57), and Leu(66)). The energetic impact of these four alanine substitutions was not caused by gross structural perturbations, since all monoclonal antibodies tested having conformation-dependent epitopes on this domain exhibited unaltered binding kinetics, These sites together with a three-dimensional structure for uPAR may provide an appropriate target for rational drug design aimed at developing new receptor binding antagonists with potential application in cancer therapy.
引用
收藏
页码:37995 / 38003
页数:9
相关论文
共 59 条
[21]   Differential roles for disulfide bonds in the structural integrity and biological activity of κ-bungarotoxin, a neuronal nicotinic acetylcholine receptor antagonist [J].
Grant, GA ;
Luetje, CW ;
Summers, R ;
Xu, XL .
BIOCHEMISTRY, 1998, 37 (35) :12166-12171
[22]   SOLUTION STRUCTURE OF THE AMINO-TERMINAL FRAGMENT OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR [J].
HANSEN, AP ;
PETROS, AM ;
MEADOWS, RP ;
NETTESHEIM, DG ;
MAZAR, AP ;
OLEJNICZAK, ET ;
XU, RX ;
PEDERSON, TM ;
HENKIN, J ;
FESIK, SW .
BIOCHEMISTRY, 1994, 33 (16) :4847-4864
[23]   Principles of protein-protein interactions [J].
Jones, S ;
Thornton, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (01) :13-20
[24]   KINETIC-ANALYSIS OF MONOCLONAL ANTIBODY-ANTIGEN INTERACTIONS WITH A NEW BIOSENSOR BASED ANALYTICAL SYSTEM [J].
KARLSSON, R ;
MICHAELSSON, A ;
MATTSSON, L .
JOURNAL OF IMMUNOLOGICAL METHODS, 1991, 145 (1-2) :229-240
[25]   THERMODYNAMIC ANALYSIS OF AN ANTIBODY FUNCTIONAL EPITOPE [J].
KELLEY, RF ;
OCONNELL, MP .
BIOCHEMISTRY, 1993, 32 (27) :6828-6835
[26]   Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay [J].
Kim, J ;
Yu, W ;
Kovalski, K ;
Ossowski, L .
CELL, 1998, 94 (03) :353-362
[27]   THE EFFECT OF ANTISENSE INHIBITION OF UROKINASE RECEPTOR IN HUMAN SQUAMOUS-CELL CARCINOMA ON MALIGNANCY [J].
KOOK, YH ;
ADAMSKI, J ;
ZELENT, A ;
OSSOWSKI, L .
EMBO JOURNAL, 1994, 13 (17) :3983-3991
[28]  
Kussmann M, 1997, J MASS SPECTROM, V32, P593
[29]   Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology [J].
List, K ;
Hoyer-Hansen, G ;
Ronne, E ;
Dano, K ;
Behrendt, N .
JOURNAL OF IMMUNOLOGICAL METHODS, 1999, 222 (1-2) :125-133
[30]  
Luther T, 1997, AM J PATHOL, V150, P1231